Roux-en-Y gastric bypass surgery increases number but not density of CCK-, GLP-1-, 5-HT-, and neurotensin-expressing enteroendocrine cells in rats

Neurogastroenterology and Motility

Volumn 25, Issue 1, 2013, Pages

  Mumphrey, M B ^a   Patterson, L M ^a   Zheng, H ^a   Berthoud, H R ^a  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

Bariatric surgery; Ghrelin; High fat diet; Hyperplasia; Intestinal wall; Obesity; Stomach

Indexed keywords

CHOLECYSTOKININ; GHRELIN; GLUCAGON LIKE PEPTIDE 1; NEUROTENSIN; PEPTIDE YY; SEROTONIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL DENSITY; CONTROLLED STUDY; ENTEROENDOCRINE CELL; HORMONE RELEASE; HYPERPLASIA; HYPERTROPHY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; ROUX EN Y GASTRIC BYPASS SURGERY; STOMACH BYPASS;

ANIMALS; CHOLECYSTOKININ; ENTEROENDOCRINE CELLS; GASTRIC BYPASS; GLUCAGON-LIKE PEPTIDE 1; IMMUNOHISTOCHEMISTRY; MALE; NEUROTENSIN; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN;

EID: 84871644871     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/nmo.12034     Document Type: Article

References (60)

1. Richards NG, Beekley AC, Tichansky DS. The economic costs of obesity and the impact of bariatric surgery. Surg Clin North Am 2011; 91: 1173-80, vii-viii.
2. Sjostrom L. Bariatric surgery and reduction in morbidity and mortality: experiences from the SOS study. Int J Obes (Lond) 2008; 32(Suppl 7): S93-7.
3. Mechanick JI, Kushner RF, Sugerman HJ et al. Executive summary of the recommendations of the American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic & Bariatric Surgery medical guidelines for clinical practice for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient. Endocr Pract 2008; 14: 318-36.
4. 2: an integrative review of early studies. Obes Surg 2010; 20: 776-90.
5. Tam CS, Berthoud HR, Bueter M et al. Could the mechanisms of bariatric surgery hold the key for novel therapies? report from a Pennington Scientific Symposium. Obes Rev 2011; 12: 984-94.
6. Cummings DE. Endocrine mechanisms mediating remission of diabetes after gastric bypass surgery. Int J Obes (Lond) 2009; 33(Suppl 1): S33-40.
7. Korner J, Inabnet W, Febres G et al. Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. Int J Obes (Lond) 2009; 33: 786-95.
8. Laferrere B, Heshka S, Wang K et al. Incretin levels and effect are markedly enhanced 1month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care 2007; 30: 1709-16.
9. le Roux CW, Aylwin SJ, Batterham RL et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 2006; 243: 108-14.
10. Meirelles K, Ahmed T, Culnan DM, Lynch CJ, Lang CH, Cooney RN. Mechanisms of glucose homeostasis after Roux-en-Y gastric bypass surgery in the obese, insulin-resistant Zucker rat. Ann Surg 2009; 249: 277-85.
11. Shin AC, Zheng H, Townsend RL, Sigalet DL, Berthoud HR. Meal-induced hormone responses in a rat model of Roux-en-Y gastric bypass surgery. Endocrinology 2010; 151: 1588-97.
12. Stylopoulos N, Davis P, Pettit JD, Rattner DW, Kaplan LM. Changes in serum ghrelin predict weight loss after Roux-en-Y gastric bypass in rats. Surg Endosc 2005; 19: 942-6.
13. Cummings DE, Weigle DS, Frayo RS et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002; 346: 1623-30.
14. Kellum JM, Kuemmerle JF, O'Dorisio TM et al. Gastrointestinal hormone responses to meals before and after gastric bypass and vertical banded gastroplasty. Ann Surg 1990; 211: 763-70; discussion 770-61.
15. Jacobsen SH, Olesen SC, Dirksen C et al. Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects. Obes Surg 2012; 22: 1084-96.
16. Culnan DM, Cooney RN, Stanley B, Lynch CJ. Apolipoprotein A-IV, a putative satiety/antiatherogenic factor, rises after gastric bypass. Obesity (Silver Spring) 2009; 17: 46-52.
17. Sigalet DL, Bawazir O, Martin GR et al. Glucagon-like peptide-2 induces a specific pattern of adaptation in remnant jejunum. Dig Dis Sci 2006; 51: 1557-66.
18. Rowland KJ, Brubaker PL. Life in the crypt: a role for glucagon-like peptide-2? Mol Cell Endocrinol 2008; 288: 63-70.
19. Brubaker PL, Izzo A, Hill M, Drucker DJ. Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. Am J Physiol 1997; 272: E1050-8.
20. Drucker DJ, Erlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci U S A 1996; 93: 7911-6.
21. Estall JL, Drucker DJ. Glucagon-like peptide-2. Annu Rev Nutr 2006; 26: 391-411.
22. Ockander L, Hedenbro JL, Rehfeld JF, Sjolund K. Jejunoileal bypass changes the duodenal cholecystokinin and somatostatin cell density. Obes Surg 2003; 13: 584-90.
23. Chan CB, Buchan AM, Green KA, Pederson RA. The effect of jejunoileal bypass (JIB) in the obese Zucker rat on a sub-group of enteroendocrine cells. Int J Obes 1987; 11: 285-93.
24. Nadreau E, Baraboi ED, Samson P et al. Effects of the biliopancreatic diversion on energy balance in the rat. Int J Obes (Lond) 2006; 30: 419-29.
25. Speck M, Cho YM, Asadi A, Rubino F, Kieffer TJ. Duodenal-jejunal bypass protects GK rats from {beta}-cell loss and aggravation of hyperglycemia and increases enteroendocrine cells coexpressing GIP and GLP-1. Am J Physiol Endocrinol Metab 2011; 300: E923-32.
26. Stearns AT, Balakrishnan A, Tavakkolizadeh A. Impact of Roux-en-Y gastric bypass surgery on rat intestinal glucose transport. Am J Physiol Gastrointest Liver Physiol 2009; 297: G950-7.
27. le Roux CW, Borg C, Wallis K et al. Gut hypertrophy after gastric bypass is associated with increased glucagon-like peptide 2 and intestinal crypt cell proliferation. Ann Surg 2010; 252: 50-6.
28. Zheng H, Shin AC, Lenard NR et al. Meal patterns, satiety, and food choice in a rat model of Roux-en-Y gastric bypass surgery. Am J Physiol Regul Integr Comp Physiol 2009; 297: R1273-82.
29. Berthoud HR, Mumphrey MB, Patterson LM, Zheng H. Roux-en-Y gastric bypass surgery-induced changes in enteroendocrine cell abundance and cytokine gene expression. Neurogastroenterol Motil 2012; 24: 132 (abstract).
30. de La Serre CB, Ellis CL, Lee J, Hartman AL, Rutledge JC, Raybould HE. Propensity to high-fat diet-induced obesity in rats is associated with changes in the gut microbiota and gut inflammation. Am J Physiol Gastrointest Liver Physiol 2010; 299: G440-8.
31. Inabnet WB, 3rd, Winegar DA, Sherif B, Sarr MG. Early outcomes of bariatric surgery in patients with metabolic syndrome: an analysis of the bariatric outcomes longitudinal database. J Am Coll Surg 2012; 214: 550-6.
32. Taqi E, Wallace LE, de Heuvel E et al. The influence of nutrients, biliary-pancreatic secretions, and systemic trophic hormones on intestinal adaptation in a Roux-en-Y bypass model. J Pediatr Surg 2010; 45: 987-95.
33. le Roux CW, Batterham RL, Aylwin SJ et al. Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology 2006; 147: 3-8.
34. Tang-Christensen M, Larsen PJ, Goke R et al. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol 1996; 271: R848-56.
35. Turton MD, O'Shea D, Gunn I et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996; 379: 69-72.
36. Wang Z, Wang RM, Owji AA, Smith DM, Ghatei MA, Bloom SR. Glucagon-like peptide-1 is a physiological incretin in rat. J Clin Invest 1995; 95: 417-21.
37. Chambers AP, Jessen L, Ryan KK et al. Weight-independent changes in blood glucose homeostasis after gastric bypass or vertical sleeve gastrectomy in rats. Gastroenterology 2011; 141: 950-8.
38. Chandarana K, Gelegen C, Karra E et al. Diet and gastrointestinal bypass-induced weight loss: the roles of ghrelin and peptide YY. Diabetes 2011; 60: 810-8.
39. Troy S, Soty M, Ribeiro L et al. Intestinal gluconeogenesis is a key factor for early metabolic changes after gastric bypass but not after gastric lap-band in mice. Cell Metab 2008; 8: 201-11.
40. Smith GP, Gibbs J, Jerome C, Pi-Sunyer FX, Kissileff HR, Thornton J. The satiety effect of cholecystokinin: a progress report. Peptides 1981; 2: 57-9.
41. Suzuki S, Ramos EJ, Goncalves CG, Chen C, Meguid MM. Changes in GI hormones and their effect on gastric emptying and transit times after Roux-en-Y gastric bypass in rat model. Surgery 2005; 138: 283-90.
42. Rubino F, Gagner M, Gentileschi P et al. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg 2004; 240: 236-42.
43. Lee WJ, Chen CY, Chong K, Lee YC, Chen SC, Lee SD. Changes in postprandial gut hormones after metabolic surgery: a comparison of gastric bypass and sleeve gastrectomy. Surg Obes Relat Dis 2011; 7: 683-90.
44. Peterli R, Steinert RE, Woelnerhanssen B et al. Metabolic and hormonal changes after laparoscopic Roux-en-Y Gastric bypass and sleeve gastrectomy: a randomized, prospective trial. Obes Surg 2012; 22: 740-8.
45. Buchan AM, Pederson RA, Koop I, Gourlay RH, Cleator IG. Morphological and functional alterations to a sub-group of regulatory peptides in human pancreas and intestine after jejuno-ileal bypass. Int J Obes Relat Metab Disord 1993; 17: 109-13.
46. Naslund E, Gryback P, Hellstrom PM et al. Gastrointestinal hormones and gastric emptying 20years after jejunoileal bypass for massive obesity. Int J Obes Relat Metab Disord 1997; 21: 387-92.
47. Sarson DL, Scopinaro N, Bloom SR. Gut hormone changes after jejunoileal (JIB) or biliopancreatic (BPB) bypass surgery for morbid obesity. Int J Obes 1981; 5: 471-80.
48. Naslund E, Gryback P, Backman L et al. Distal small bowel hormones: correlation with fasting antroduodenal motility and gastric emptying. Dig Dis Sci 1998; 43: 945-52.
49. Sirinek KR, O'Dorisio TM, Howe B, McFee AS. Neurotensin, vasoactive intestinal peptide, and Roux-en-Y gastrojejunostomy. Their role in the dumping syndrome. Arch Surg 1985; 120: 605-9.
50. Christ-Crain M, Stoeckli R, Ernst A et al. Effect of gastric bypass and gastric banding on proneurotensin levels in morbidly obese patients. J Clin Endocrinol Metab 2006; 91: 3544-7.
51. Holdstock C, Zethelius B, Sundbom M, Karlsson FA, Eden Engstrom B. Postprandial changes in gut regulatory peptides in gastric bypass patients. Int J Obes (Lond) 2008; 32: 1640-6.
52. Cummings DE, Overduin J, Foster-Schubert KE. Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab 2004; 89: 2608-15.
53. Fruhbeck G, Diez-Caballero A, Gil MJ et al. The decrease in plasma ghrelin concentrations following bariatric surgery depends on the functional integrity of the fundus. Obes Surg 2004; 14: 606-12.
54. Stoeckli R, Chanda R, Langer I, Keller U. Changes of body weight and plasma ghrelin levels after gastric banding and gastric bypass. Obes Res 2004; 12: 346-50.
55. Holdstock C, Engstrom BE, Ohrvall M, Lind L, Sundbom M, Karlsson FA. Ghrelin and adipose tissue regulatory peptides: effect of gastric bypass surgery in obese humans. J Clin Endocrinol Metab 2003; 88: 3177-83.
56. Korner J, Inabnet W, Conwell IM et al. Differential effects of gastric bypass and banding on circulating gut hormone and leptin levels. Obesity (Silver Spring) 2006; 14: 1553-61.
57. Rodieux F, Giusti V, D'Alessio DA, Suter M, Tappy L. Effects of gastric bypass and gastric banding on glucose kinetics and gut hormone release. Obesity (Silver Spring) 2008; 16: 298-305.
58. Lomax AE, Linden DR, Mawe GM, Sharkey KA. Effects of gastrointestinal inflammation on enteroendocrine cells and enteric neural reflex circuits. Auton Neurosci 2006; 127: 250-7.
59. Grundy D. 5-HT system in the gut: roles in the regulation of visceral sensitivity and motor functions. Eur Rev Med Pharmacol Sci 2008; 12(Suppl 1): 63-7.
60. Crowell MD, Wessinger SB. 5-HT and the brain-gut axis: opportunities for pharmacologic intervention. Expert Opin Investig Drugs 2007; 16: 761-5.